Lead Sponsor

Pfizer

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Clinical diagnosis of chronic moderate-to-severe atopic dermatitis (AD) for at least 1 year
•Recent history of inadequate response to medicated topical therapy for AD or required systemic therapy to control disease
•Moderate-to-severe AD defined as affected BSA at least 10%, IGA at least 3, EASI at least 16, Peak Pruritus NRS at least 4

•A current or past medical history of conditions associated with thrombocytopenia, coagulopathy, or platelet dysfunction
•Currently have active forms of other inflammatory skin diseases, i.e. not AD, or have evidence of skin conditions (e.g. psoriasis, seborrheic dermatitis, lupus) at the time of Day 1 that would interfere with evaluation of AD or response to treatment
•Participants who have received prior treatment with any systemic JAK inhibitors
•Require treatment with prohibited concomitant medication(s) or have received a prohibited concomitant medication within specified time frames prior to the first dose of study medication, including topical treatments that could affect AD
•Pregnant or breastfeeding women or sexually-active women of childbearing potential who are unwilling to use contraception